Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Recent updates highlight Lynparza's significant survival benefits in early breast cancer and the breakthrough therapy designation for Datopotamab deruxtecan in advanced lung cancer, while previous submissions and trial results for Tezspire have been removed.
    Difference
    69%
    Check dated 2024-12-14T12:12:21.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    AstraZeneca has received Priority Review for Imfinzi in the US for muscle-invasive bladder cancer and has approved it as the first immunotherapy for limited-stage small cell lung cancer, while Iskra Reic has been appointed as Executive Vice President, International.
    Difference
    66%
    Check dated 2024-12-07T10:08:04.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The CAPItello-281 Phase III trial reported that the Truqap combination significantly improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer.
    Difference
    10%
    Check dated 2024-11-30T08:36:03.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Tagrisso has been recommended for approval in the EU for patients with unresectable EGFR-mutated lung cancer, highlighting a significant advancement in treatment options.
    Difference
    59%
    Check dated 2024-11-23T03:50:21.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    AstraZeneca has made significant investments in R&D and manufacturing in the US, while also submitting a new BLA for Datopotamab deruxtecan for advanced lung cancer, and reporting positive results for Koselugo in treating neurofibromatosis type 1.
    Difference
    33%
    Check dated 2024-11-15T22:15:53.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The website has added a comprehensive search menu and new sections highlighting AstraZeneca's R&D approach, therapy areas, sustainability efforts, and recent clinical trial results, while removing specific details about recent drug approvals and trial outcomes.
    Difference
    100%
    Check dated 2024-11-08T17:52:16.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.